Cabaletta Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cabaletta Bio Inc (CABA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cabaletta Bio Inc vs Its Competitors
- Scale: Cabaletta Bio Inc ranks #81 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Cabaletta Bio Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cabaletta Bio Inc | - | - | - | Yes |
| Competitors combined (41) | ||||
| High-Confidence Competitors (8) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CABA Stock Performance relative to its Competitors
CABA Stock Performance relative to High-Confidence Competitors
CABA Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Century Therapeutics inc | 282.9% | Outperformed |
| 3 | Immix Biopharma Inc | 282.9% | Outperformed |
| 4 | Replimune Group Inc | 282.9% | Outperformed |
| 5 | Exelixis Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cabaletta Bio Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cabaletta Bio Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cabaletta Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cabaletta Bio Inc |
201.04 | - |
 Amgen Inc |
255,014.76 | 38,903.00 |
 Gilead Sciences Inc |
210,105.45 | 30,988.00 |
 Moderna Inc |
92,077.30 | 2,228.00 |
 Argenx Se |
64,796.45 | 8,399.37 |
 Exelixis Inc |
17,861.86 | 2,496.86 |
| SUBTOTAL | 661,896.08 | 85,367.79 |
Sign in to see all competitors of Cabaletta Bio Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cabaletta Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cabaletta Bio Inc's Competitors Named by the Company
Competitive relationships identified from Cabaletta Bio Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis Pharmaceuticals Corporation | Company report | 85% |
| Johnson and Johnson, Inc. | Company report | 85% |
| Bristol Myers Squibb | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Autolus | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Celyad Oncology Sa | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Tcr2 Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Cabaletta Bio Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Cabaletta Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Prime Medicine Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Cabaletta Bio Inc .
Cabaletta Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cabaletta Bio Inc | 201 | - | -1,162,295 |
| Amgen Inc | 255,015 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 210,105 | 1,822,824 | -227,235 |
| Moderna Inc | 92,077 | 474,043 | -670,426 |
| Argenx Se | 64,796 | 7,316,521 | 1,125,466 |
| Exelixis Inc | 17,862 | 2,176,862 | 1,454,397 |
| PEERS TOTAL | 661,695 | 1,956,720 | 48,603 |
Sign in to see all peers for Cabaletta Bio Inc .
Cabaletta Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Exelixis Inc | United States 92.47 % |
| Novavax inc | United States 68.88 % |
| 4d Molecular Therapeutics Inc | JP 97.05 % |
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cabaletta Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 157 companies in Cabaletta Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cabaletta Bio Inc ranks #81 of 157 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,443, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 254,081 | 27.22 % |
| 2 | Gilead Sciences Inc | 208,762 | 22.37 % |
| 3 | Moderna Inc | 92,077 | 9.86 % |
| 4 | Argenx Se | 64,796 | 6.94 % |
| 5 | Biogen Inc | 1,234 | 5.2% |
| 6 | Revolution Medicines Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Kymera Therapeutics Inc | 1,234 | 5.2% |
| 81 | Cabaletta Bio Inc | 201 | 0.02 % |
Market cap and industry share for the rest of Cabaletta Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Cabaletta Bio Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 76 | Protalix Biotherapeutics inc | 244 | 42.02 % |
| 77 | Palisade Bio Inc | 241 | -37.58 % |
| 78 | Quince Therapeutics Inc | 235 | - |
| 79 | Armata Pharmaceuticals Inc | 231 | -42.96 % |
| 80 | Precision Biosciences Inc | 1,234 | 12.3% |
| 81 | Cabaletta Bio Inc | 201 | -44.13 % |
| 82 | Compugen Ltd | 1,234 | 12.3% |
| 83 | Invivyd Inc | 1,234 | 12.3% |
| 84 | Prokidney Corp | 1,234 | 12.3% |
| 85 | Fate Therapeutics Inc | 1,234 | 12.3% |
| 86 | Engene Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Cabaletta Bio Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-12. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Cabaletta Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 3.5x | 5.1x | -1.6x |
| Return on Equity | -128.27 % | industry aggregate | -126.73 % |
| Return on Invested Capital | -64.65 % | -11.27 % (avg) | -53.38 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cabaletta Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | - | -14.00 % | -21.86 % | -22.39 % | -33.17 % | -61.26 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cabaletta Bio Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Cabaletta Bio Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Cabaletta Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,443 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Cabaletta Bio Inc's dedicated Suppliers and Customers pages, not here.
Cabaletta Bio Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Cabaletta Bio Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cabaletta Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 126.7 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (57.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Cabaletta Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cabaletta Bio Inc | 2.73 | 3.70 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Argenx Se | 2.64 | 5.23 | - |
| Exelixis Inc | 0.84 | 3.37 | - |
Sign in to see all peers for Cabaletta Bio Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cabaletta Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cabaletta Bio Inc | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Exelixis Inc | Q3 2026 | +10.2 % | -51.1 % |
| PEERS TOTAL | +24.3 % | +18.6 % |
Sign in to see all peers for Cabaletta Bio Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cabaletta Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cabaletta Bio Inc | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Exelixis Inc | Q3 2026 | +41.2 % | +67.9 % |
Sign in to see all peers for Cabaletta Bio Inc .
Cabaletta Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cabaletta Bio Inc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Moderna Inc | - | - | - |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Exelixis Inc | 63.88% | 75.01% | 85.83% |
Sign in to see all peers for Cabaletta Bio Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cabaletta Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cabaletta Bio Inc | - | - |
| Amgen Inc | 27.08 | 6.56 |
| Gilead Sciences Inc | - | 6.78 |
| Moderna Inc | - | 41.33 |
| Argenx Se | 50.14 | 7.71 |
| Exelixis Inc | 28.74 | 7.15 |
| PEERS AVERAGE | 341.33 | 7.75 |
Sign in to see all peers for Cabaletta Bio Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.